PR on AACR stuff:
>>FREMONT, Calif., April 4 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) highlighted today two studies being presented at the 97th annual American Association of Cancer Research (AACR) conference which is running from April 1-5 in Washington, D.C.
In multiple previous studies, Ciphergen and its collaborators have discovered, identified, and validated seven serum/plasma biomarkers for the detection of ovarian cancer. In a study being presented today, researchers from The Johns Hopkins University School of Medicine, Righospitalet, University of Copenhagen, Denmark, and the Danish Cancer Society independently validated the seven biomarkers using prospectively collected serum samples. This study concluded that this seven biomarker panel in combination with CA- 125 improves the discrimination of ovarian cancer from benign pelvic masses, including endometriosis and benign ovarian cysts. The prospective nature of the study and the blinded training and testing provided an independent validation of the seven biomarkers.
As part of Ciphergen's breast cancer program, researchers from The Johns Hopkins Medical Institutions, National Cancer Institute, and M.D. Anderson Cancer Center presented today at AACR the latest developments in a paper titled, "Discovery of serum proteomic biomarkers for the early detection of breast cancer- a multi-center study." The original study in this program by Li et al. (Clinical Chemistry 48(8) 1296-1304) published in 2002 detailed the discovery of three serum biomarkers that can improve detection of breast cancer. Two of the three markers have been identified and validated by two recent studies (Li et al. (Clinical Chemistry 51, p. 2229-2235) and Mathelin et al, (Breast Cancer Res Treatment 96, p. 83-90)). In this presentation at AACR, the researchers report the discovery of additional biomarkers in a multi-institutional study that improved the performance of the current biomarker panel. Identification and characterization of these biomarkers are currently underway.
"These studies and others that will be featured at AACR demonstrate the potential for improved patient care as these discoveries are translated into new diagnostic and theranostic tests based on Ciphergen's SELDI ProteinChip® Technology," stated Gail S. Page, President and CEO of Ciphergen.<<
snip
I've been too busy with moving and marriage to look at the abstracts, but will at least know which ones to look at when I get the chance. Stock price flapping around a bit today. I predict little further movement until launch . . . absent news in other indications.
Cheers, Tuck |
